FluoGuide A/S publishes interim report for the period January – September 2022
Copenhagen, Denmark, 24 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 September 2022. The Q3 report is available as an attached document to this press release and on FluoGuide’s website: Filings & reports - FluoGuide A/S In Q3 2022, FluoGuide made important progress and received approvals from Danish authorities to initiate the clinical phase IIb trial with FG001 in aggressive brain cancer as well as clinical phase IIa trial with FG001 in head and neck cancer in Denmark.